Canaccord raised the firm’s price target on Tenaya Therapeutics (TNYA) to $18 from $16 and keeps a Buy rating on the shares. The firm said its 3Q24 earnings report was straightforward, with the more notable news coming earlier in the quarter with the announcement of positive safety updates to cohort 1 of TN-201’s MyPEAK-1 Ph1b/2 clinical trial, and confirmation that more detailed interim data from cohort 1 will come in December.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter